trending Market Intelligence /marketintelligence/en/news-insights/trending/gewxj6yuvwswqpyrrsrpjq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Surface Oncology's multiple myeloma medicine gets US FDA orphan drug status

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Surface Oncology's multiple myeloma medicine gets US FDA orphan drug status

Surface Oncology Inc. said the U.S. Food and Drug Administration granted orphan drug designation to its medicine SRF231 for treating a type of blood cancer known as multiple myeloma.

The Cambridge, Mass.-based company said investigational drug SRF231 is being evaluated in a phase 1 trial to assess safety and tolerability.

The FDA's orphan drug status is granted to drugs intended to treat rare diseases that affect fewer than 200,000 people in the U.S. The designation provides certain benefits, including a potential seven-year market exclusivity for the drug upon approval.

Surface Oncology went public in April, raising about $108 million in its IPO.